Trial · NCT03808688

Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting

NCT03808688, Phase 4, Completed, Aerie Pharmaceuticals; results first posted 2020-09-29

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting. Trials, record NCT03808688. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03808688

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting
NCT number: NCT03808688
Status: Completed
Phases: Phase 4
Enrollment: 261 participants, actual
Lead sponsor: Aerie Pharmaceuticals
Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Netarsudil Ophthalmic Solution 0.02%
First posted: 2019-01-17
Last updated: 2020-09-29
Results first posted: 2020-09-29

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Intraocular Pressure (IOP)	12 weeks	Percent Change from Baseline IOP at Week 12, as measured by Goldmann applanation tonometry. Prostaglandin analog (PGA). Fixed dose combination (FDC).

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Intraocular Pressure (IOP)	12 weeks	Modified Intent-to-Treat (mITT) population included all subjects who received at least 1 dose of study medication and had at least 1 follow-up visit with a completed IOP measurement.	percent change	MEAN

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Intraocular Pressure (IOP)	Netarsudil Ophth Sol 0.02% Monotherapy - Tx Naïve At Baseline	-16.9	Standard Deviation 16.35	percent change
Intraocular Pressure (IOP)	Netarsudil Ophth Sol 0.02% Monotherapy - Replaced 1 Agent	-2.3	Standard Deviation 16.23	percent change
Intraocular Pressure (IOP)	Netarsudil Ophth Sol 0.02% Monotherapy - Replaced 2 Agents	0.2	Standard Deviation 8.81	percent change
Intraocular Pressure (IOP)	Netarsudil Ophth Sol 0.02% Concomitant Therapy	-17.0	Standard Deviation 16.81	percent change

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Netarsudil Ophthalmic Solution 0.02% Monotherapy	99
Overall Study	STARTED	Netarsudil Ophthalmic Solution 0.02% Concomitant Therapy	161
Overall Study	COMPLETED	Netarsudil Ophthalmic Solution 0.02% Monotherapy	81
Overall Study	COMPLETED	Netarsudil Ophthalmic Solution 0.02% Concomitant Therapy	138
Overall Study	NOT COMPLETED	Netarsudil Ophthalmic Solution 0.02% Monotherapy	18
Overall Study	NOT COMPLETED	Netarsudil Ophthalmic Solution 0.02% Concomitant Therapy	23

Source ClinicalTrials.gov

Adverse events14

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Conjunctival Hyperemia	Eye disorders	Netarsudil Ophthalmic Solution 0.02% Monotherapy	22	99	22
other	Conjunctival Hyperemia	Eye disorders	Netarsudil Ophthalmic Solution 0.02% Concomitant Therapy	32	161	32
other	Vision Blurred	Eye disorders	Netarsudil Ophthalmic Solution 0.02% Monotherapy	9	99	9
other	Vision Blurred	Eye disorders	Netarsudil Ophthalmic Solution 0.02% Concomitant Therapy	10	161	10
other	Conjunctival Hemorrage	Eye disorders	Netarsudil Ophthalmic Solution 0.02% Monotherapy	6	99	6
other	Conjunctival Hemorrage	Eye disorders	Netarsudil Ophthalmic Solution 0.02% Concomitant Therapy	8	161	8
other	Instillation Site Pain	Eye disorders	Netarsudil Ophthalmic Solution 0.02% Monotherapy	6	99	6
other	Instillation Site Pain	Eye disorders	Netarsudil Ophthalmic Solution 0.02% Concomitant Therapy	8	161	8
serious	Cellulitis Lower Left Extremity	Infections and infestations	Netarsudil Ophthalmic Solution 0.02% Monotherapy	0	99	0
serious	Cellulitis Lower Left Extremity	Infections and infestations	Netarsudil Ophthalmic Solution 0.02% Concomitant Therapy	1	161	1

1 to 10 of 14Source ClinicalTrials.gov

See all 14 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Netarsudil Ophthalmic Solution 0.02% Monotherapy	0	99
Total, all-cause mortality	Netarsudil Ophthalmic Solution 0.02% Concomitant Therapy	0	161
Total, other adverse events	Netarsudil Ophthalmic Solution 0.02% Monotherapy	43	99
Total, other adverse events	Netarsudil Ophthalmic Solution 0.02% Concomitant Therapy	58	161
Total, serious adverse events	Netarsudil Ophthalmic Solution 0.02% Monotherapy	2	99
Total, serious adverse events	Netarsudil Ophthalmic Solution 0.02% Concomitant Therapy	1	161

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
33733980	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Netarsudil Ophthalmic Solution 0.02% Monotherapy vs Netarsudil Ophthalmic Solution 0.02% Concomitant Therapy: deaths from any cause	Trial comparisons
Netarsudil Ophthalmic Solution 0.02% Monotherapy vs Netarsudil Ophthalmic Solution 0.02% Concomitant Therapy: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03808688

GET https://conductscience.org/api/trials/v1/NCT03808688/registered

API reference For AI assistants